Document:

Exhibit 10.1

 

EXECUTION VERSION

 

AMENDMENT No. 1, dated as of January 19, 2017 (this “Amendment”) to the Amended and Restated Credit Agreement dated as of July 17, 2015, among SUMMIT MATERIALS, LLC, a Delaware limited liability company (the “Borrower”), the Guarantors party thereto, the several banks and other financial institutions or entities from time to time parties to the Credit Agreement (the “Lenders”), BANK OF AMERICA, N.A., as Administrative Agent (the “Administrative Agent”), Collateral Agent, L/C Issuer and Swing Line Lender and the other parties thereto (as amended, restated, modified and supplemented from time to time, the “Credit Agreement”); capitalized terms used and not otherwise defined herein shall have the meanings assigned to such terms in the Credit Agreement.

 

WHEREAS, the Borrower desires to amend the Credit Agreement on the terms set forth herein;

 

WHEREAS, Section 10.01 of the Credit Agreement provides that the parties hereto may amend the Credit Agreement for the purposes set forth herein;

 

NOW, THEREFORE, in consideration of the premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

 

Section 1.              Amendments.

 

Part I

 

Effective upon receipt by the Administrative Agent of executed counterparts to this Amendment from the Borrower and Lenders constituting the Required Lenders, the Credit Agreement is hereby amended as follows:

 

(a)           The following new definition is hereby added to Section 1.01 of the Credit Agreement:

 

““Amendment No. 1” means Amendment No. 1 to this Agreement dated as of January 19, 2017.”

 

(b)           Section 3.07(b) of the Credit Agreement is hereby amended by inserting a new final sentence thereof as follows:

 

“Notwithstanding the foregoing, in connection with Amendment No. 1, the Borrower shall not be required to provide ten (10) Business Days’ prior written notice to the Administrative Agent and any Non-Consenting Lender and any Non-Consenting Lender with Restatement Effective Date Term Loans shall not be required to sign an Assignment and Assumption with respect to any required assignment of its Restatement Effective Date Term Loans pursuant to this Section 3.07 and the assignment of any Non-Consenting Lender’s Restatement Effective Date Term Loans to an assignee pursuant to this Section 3.07 shall become effective immediately upon receipt by (i) such Non-Consenting Lender of a notice that all Non-Consenting Lender’s Restatement Effective Date Term Loans are being 

 

 

required to be assigned to such assignee, which notice shall be signed by the Borrower, the Administrative Agent and the assignee and (ii) the Administrative Agent (for the account of such Non-Consenting Lender) of immediately available funds in an amount from (x) such assignee equal to the principal amount of such Non-Consenting Lender’s Restatement Effective Date Term Loan and (y) the Borrower equal to the amount of accrued and unpaid interest on such Non-Consenting Lender’s Restatement Effective Date Term Loan to but excluding the date of such payment.”

 

Part II

 

The Credit Agreement is hereby amended effective as of the Amendment No. 1 Effective Date (as defined below) and after giving effect to Part I of this Amendment as follows:

 

(a)           The following new definition is hereby added to Section 1.01 of the Credit Agreement in alphabetical order:

 

““Amendment No. 1 Effective Date” has the meaning set forth in Amendment No. 1.”

 

(b)           Clause (a) of the definition of “Applicable Rate” appearing in Section 1.01 of the Credit Agreement is hereby amended by amending and restating it in its entirety as follows:

 

“(a) with respect to Restatement Effective Date Term Loans: (x) a percentage per annum equal to: (A) for Eurocurrency Rate Loans, 2.75% and (B) for Base Rate Loans, 1.75%.”

 

(c)           Section 1.01 of the Credit Agreement is hereby amended by deleting the definition of “Base Rate” contained therein in its entirety and replacing it with the following:

 

““Base Rate” means for any day a fluctuating rate per annum equal to the highest of (a) the Federal Funds Rate plus 1/2 of 1% (b) the Prime Rate in effect for such day and (c) the Eurocurrency Rate plus 1.00%; it being understood that, for the avoidance of doubt, solely with respect to the Restatement Effective Date Term Loans, the Base Rate shall be deemed to be not less than 1.75% per annum.”

 

(d)           Section 1.01 of the Credit Agreement is hereby amended by deleting the definition of “Eurocurrency Rate” contained therein in its entirety and replacing it with the following:

 

““Eurocurrency Rate” means:

 

(a)           for any Interest Period with respect to a Eurocurrency Rate Loan, the rate per annum equal to the London Interbank Offered Rate (“LIBOR”) or a comparable or successor rate, which rate is approved by the Administrative Agent, as published on the

 

2

 

applicable Bloomberg screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time) at approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period, for Dollar deposits (for delivery on the first day of such Interest Period) with a term equivalent to such Interest Period; and

 

(b)           for any interest calculation with respect to a Base Rate Loan on any date, the rate per annum equal to LIBOR, at or about 11:00 a.m., London time determined two Business Days prior to such date for Dollar deposits with a term of one month commencing that day;

 

provided that to the extent a comparable or successor rate is approved by the Administrative Agent in connection herewith, the approved rate shall be applied in a manner consistent with market practice; provided, further that to the extent such market practice is not administratively feasible for the Administrative Agent, such approved rate shall be applied in a manner as otherwise reasonably determined by the Administrative Agent; provided, further, that solely with respect to the Restatement Effective Date Term Loans, the Eurocurrency Rate shall be deemed to not be less than 0.75% per annum in all cases.”

 

(e)           Section 1.01 of the Credit Agreement is hereby amended by deleting the definition of “Federal Funds Rate” contained therein in its entirety and replacing it with the following:

 

““Federal Funds Rate” means, for any day, the rate per annum equal to the weighted average of the rates on overnight Federal funds transactions with members of the Federal Reserve System, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day; provided that (a) if such day is not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day, and (b) if no such rate is so published on such next succeeding Business Day, the Federal Funds Rate for such day shall be the average rate (rounded upward, if necessary, to a whole multiple of 1/100 of 1%) charged to Bank of America on such day on such transactions as determined by the Administrative Agent.”

 

(f)            Clause (a)(iv) of Section 2.05 is hereby amended by amending and restating in its entirety as follows:

 

“(iv)        In the event that following, but not including, the Amendment No. 1 Effective Date and on or prior to the six-month anniversary of the Amendment No. 1 Effective Date, the Borrower (x) prepays, refinances, substitutes or replaces any Restatement Effective Date Term Loans pursuant to a Repricing Transaction (including, for avoidance of doubt, any prepayment made pursuant to Section 2.05(b)(iv) that constitutes a Repricing Transaction), or (y) effects any amendment, amendment and restatement or other modification of this Agreement resulting in a Repricing Transaction, the Borrower

 

3

 

shall pay to the Administrative Agent, for the ratable account of each of the applicable Term Lenders, (1) in the case of clause (x), a prepayment premium of 1.00% of the aggregate principal amount of the Restatement Effective Date Term Loans so prepaid, refinanced, substituted or replaced and (2) in the case of clause (y), a fee equal to 1.00% of the aggregate principal amount of the applicable Restatement Effective Date Term Loans amended or otherwise modified pursuant to such amendment. If, following, but not including, the Amendment No. 1 Effective Date and on or prior to the six-month anniversary of the Amendment No. 1 Effective Date, any Term Lender that is a Non-Consenting Lender and is replaced pursuant to Section 3.07(a) in connection with any amendment, amendment and restatement or other modification of this Agreement resulting in a Repricing Transaction, such Term Lender (and not any Person who replaces such Term Lender pursuant to Section 3.07(a)) shall receive its pro rata portion (as determined immediately prior to it being so replaced) of the prepayment premium or fee described in the preceding sentence. Such amounts shall be due and payable on the date of effectiveness of such Repricing Transaction.”

 

Section 2.              Representations and Warranties, No Default.  The Borrower hereby represents and warrants that as of the Amendment No. 1 Effective Date (i) no Default or Event of Default exists and is continuing and (ii) all representations and warranties of the Loan Parties contained in the Credit Agreement and the other Loan Documents are true and correct in all material respects on and as of the date hereof, as though made on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they were true and correct in all material respects as of such earlier date (provided that representations and warranties that are qualified by materiality are true and correct (after giving effect to any qualification thereof) in all respects on and as of the date hereof or as of the specifically referenced earlier date, as the case may be).

 

Section 3.              Effectiveness.  The amendments set forth in Part I of Section 1 of this Amendment shall become effective as provided therein.   The amendments set forth in Part II of Section 1 of this Amendment shall become effective on the date (such date, the “Amendment No. 1 Effective Date”) on which each of the following conditions has been satisfied:

 

(a)           The Administrative Agent shall have received executed signature pages hereto from (i) the Required Lenders under and as defined in the Credit Agreement, (ii) each Lender with a Restatement Effective Date Term Loan and (iii) each of the Loan Parties;

 

(b)           Bank of America, N.A shall have received (i) all fees required to be paid on the effective date of this Amendment as separately agreed between the Borrower and Bank of America, N.A. (or its affiliate) and (ii) payment of all expenses required to be paid or reimbursed under Section 10.04(a) of the Credit Agreement for which invoices have been presented a reasonable period of time prior to the Amendment No. 1 Effective Date;

 

(c)           The Administrative Agent shall have received reasonably satisfactory evidence of authorization of this Amendment by the Loan Parties and a certificate of a Responsible Officer of the Borrower to the effect set forth in Section 2 above.

 

4

 

(d)           The Administrative Agent shall have received from the Borrower all accrued and unpaid interest on the Restatement Effective Date Term Loans to but excluding the Amendment No. 1 Effective Date.

 

The amendments contemplated hereby shall apply only from and after the date of effectiveness of this Amendment.

 

Section 4.              Applicable Law.

 

(a)           THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

 

(b)           ANY LEGAL ACTION OR PROCEEDING ARISING UNDER THIS AMENDMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS AMENDMENT, OR THE TRANSACTIONS RELATED HERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, MAY BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK OR OF THE UNITED STATES FOR THE SOUTHERN DISTRICT OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN IN NEW YORK CITY, AND BY EXECUTION AND DELIVERY OF THIS AMENDMENT, EACH PARTY HERETO CONSENTS, FOR ITSELF AND IN RESPECT OF ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THOSE COURTS.  EACH PARTY HERETO IRREVOCABLY WAIVES ANY OBJECTION, INCLUDING ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON THE GROUNDS OF FORUM NON CONVENIENS, WHICH IT MAY NOW OR HEREAFTER HAVE TO THE BRINGING OF ANY ACTION OR PROCEEDING IN SUCH JURISDICTION IN RESPECT OF THIS AMENDMENT OR ANY OTHER DOCUMENT RELATED HERETO.  EACH PARTY HERETO WAIVES PERSONAL SERVICE OF ANY SUMMONS, COMPLAINT OR OTHER PROCESS, WHICH MAY BE MADE BY ANY OTHER MEANS PERMITTED BY NEW YORK LAW.

 

Section 5.              Headings.  The headings of this Amendment are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.

 

Section 6.              Effect of Amendment.  Except as expressly set forth herein, (i) this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of or otherwise affect the rights and remedies of the Lenders, the Administrative Agent or the Collateral Agent, in each case under the Credit Agreement or any other Loan Document, and (ii) shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other provision of either such agreement or any other Loan Document.  Each and every term, condition, obligation, covenant and agreement contained in the Credit Agreement or any other Loan Document is hereby ratified and re-affirmed in all respects and shall continue in full force and effect.  Each Loan Party reaffirms its obligations under the Loan Documents to which it is party and the validity of the Liens granted by it pursuant to the Security Documents.  This Amendment shall constitute a

 

5

 

Loan Document for purposes of the Credit Agreement and from and after the date of effectiveness, all references to the Credit Agreement in any Loan Document and all references in the Credit Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Credit Agreement, shall, unless expressly provided otherwise, refer to the Credit Agreement as amended by this Amendment.  Each of the Loan Parties hereby consents to this Amendment and confirms that all obligations of such Loan Party under the Loan Documents to which such Loan Party is a party shall continue to apply to the Credit Agreement as amended hereby.

 

Section 7.              WAIVER OF RIGHT TO TRIAL BY JURY.

 

THE PARTIES HERETO EACH WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF OR RELATED TO THIS AMENDMENT IN ANY ACTION, PROCEEDING OR OTHER LITIGATION OF ANY TYPE BROUGHT BY ANY OF THE PARTIES AGAINST ANY OTHER PARTY OR ANY AGENT-RELATED PERSON, PARTICIPANT OR ASSIGNEE, WHETHER WITH RESPECT TO CONTRACT CLAIMS, TORT CLAIMS, OR OTHERWISE.  THE PARTIES HERETO EACH AGREE THAT ANY SUCH CLAIM OR CAUSE OF ACTION SHALL BE TRIED BY A COURT TRIAL WITHOUT A JURY.  WITHOUT LIMITING THE FOREGOING, THE PARTIES FURTHER AGREE THAT THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY IS WAIVED BY OPERATION OF THIS SECTION AS TO ANY ACTION, COUNTERCLAIM OR OTHER PROCEEDING WHICH SEEKS, IN WHOLE OR IN PART, TO CHALLENGE THE VALIDITY OR ENFORCEABILITY OF THIS AMENDMENT OR ANY PROVISION HEREOF.

 

Section 8.              Lead Arrangers and Lead Bookrunners.  Bank of America, N.A., Barclays Bank PLC, Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Goldman Sachs Bank USA and Royal Bank of Canada are the lead arrangers and bookrunners for this Amendment and shall be entitled to all rights, privileges and immunities applicable to the “Lead Arrangers” under the Loan Documents in connection herewith.

 

[Signature Pages Follow]

 

6

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the day and year first above written.

 

	
 
    	
 
    	
SUMMIT MATERIALS, LLC
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Anne L. Benedict
    
	
 
    	
 
    	
 
    	
Name:
    	
Anne   L. Benedict
    
	
 
    	
 
    	
 
    	
Title:
    	
Chief   Legal Officer
    

 

[Signature Page to Summit Amendment]

 

 

	
 
    	
 
    	
SUMMIT   MATERIALS INTERMEDIATE HOLDINGS, LLC
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Anne L. Benedict
    
	
 
    	
 
    	
 
    	
Name:
    	
Anne L. Benedict
    
	
 
    	
 
    	
 
    	
Title:
    	
Secretary
    

 

[Signature Page to Summit Amendment]

 

 

	
 
    	
ALLEYTON RESOURCE COMPANY, LLC
    
	
 
    	
ALLEYTON SERVICES COMPANY, LLC
    
	
 
    	
AMERICAN MATERIALS COMPANY, LLC
    
	
 
    	
AUSTIN MATERIALS, LLC
    
	
 
    	
B&B RESOURCES, INC.
    
	
 
    	
BOURBON LIMESTONE COMPANY
    
	
 
    	
BOXLEY MATERIALS COMPANY
    
	
 
    	
BUCKHORN MATERIALS, LLC
    
	
 
    	
COLORADO COUNTY SAND & GRAVEL CO., L.L.C.
    
	
 
    	
CON-AGG OF MO, L.L.C.
    
	
 
    	
CONCRETE SUPPLY OF TOPEKA, INC.
    
	
 
    	
CONTINENTAL CEMENT COMPANY, L.L.C.
    
	
 
    	
CORNEJO & SONS, L.L.C.
    
	
 
    	
ELAM CONSTRUCTION, INC.
    
	
 
    	
GREEN AMERICA RECYCLING, LLC
    
	
 
    	
HAMM, INC.
    
	
 
    	
H.C. RUSTIN CORPORATION
    
	
 
    	
HINKLE CONTRACTING COMPANY, LLC
    
	
 
    	
INDUSTRIAL ASPHALT, LLC
    
	
 
    	
KILGORE COMPANIES, LLC
    
	
 
    	
LEGRAND JOHNSON CONSTRUCTION CO.
    
	
 
    	
LEWIS & LEWIS, INC.
    
	
 
    	
N.R. HAMM CONTRACTOR, LLC
    
	
 
    	
N.R. HAMM QUARRY, LLC
    
	
 
    	
PELICAN ASPHALT COMPANY, LLC
    
	
 
    	
PENNY’S CONCRETE AND READY MIX, L.L.C.
    
	
 
    	
R.D. JOHNSON EXCAVATING COMPANY, LLC
    
	
 
    	
RK HALL, LLC
    
	
 
    	
SCS MATERIALS, LLC
    
	
 
    	
SIERRA READY MIX LIMITED LIABILITY COMPANY
    
	
 
    	
SUMMIT FINANCE GROUP, LLC
    
	
 
    	
SUMMIT MATERIALS CORPORATIONS I, INC.
    
	
 
    	
SUMMIT MATERIALS INTERNATIONAL, LLC
    
	
 
    	
TROY VINES, INCORPORATED
    

 

 

	
 
    	
 
    	
By:
    	
/s/ Anne L. Benedict
    
	
 
    	
 
    	
 
    	
Name:
    	
Anne L. Benedict
    
	
 
    	
 
    	
 
    	
Title:
    	
Secretary
    

 

[Signature Page to Summit Amendment]

 

 

	
 
    	
 
    	
KILGORE   PARTNERS, L.P.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:    Summit Materials, LLC, its   general partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Anne L. Benedict
    
	
 
    	
 
    	
 
    	
Name:
    	
Anne L. Benedict
    
	
 
    	
 
    	
 
    	
Title:
    	
Chief Legal Officer
    

 

[Signature Page to Summit Amendment]

 

 

	
 
    	
 
    	
BANK   OF AMERICA, N.A.,
    
	
 
    	
 
    	
as Administrative Agent and Collateral Agent
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Gregory Roetting
    
	
 
    	
 
    	
 
    	
Name:
    	
Gregory Roetting
    
	
 
    	
 
    	
 
    	
Title:
    	
Vice President
    

 

[Signature Page to Summit Amendment]

 

 

	
 
    	
 
    	
BANK   OF AMERICA, N.A.,
    
	
 
    	
 
    	
as L/C Issuer, Swingline Lender and a Lender
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/ Gregory Roetting
    
	
 
    	
 
    	
 
    	
Name:
    	
 Gregory Roetting
    
	
 
    	
 
    	
 
    	
Title:
    	
Vice President
    
	
 
    	
 
    	
 
    	
 
    

[Signature Page to Summit Amendment]

 

 

[The Consents of the Consenting Lenders are on file with the Administrative Agent.]Exhibit 10.1

 

FORM OF Parent VOTING AGREEMENT

 

This VOTING AGREEMENT (this
“Agreement”), dated as of January 18, 2017, is by and between, Altimmune, Inc., a Delaware corporation
(the “Company”), and each of the undersigned stockholders (each, a “Stockholder,”
and, collectively, the “Stockholders”) of PharmAthene, Inc., a Delaware corporation (“Parent”),
identified on the signature page hereto.

 

A.           The
Company, Parent, Mustang Merger Sub Corp I Inc., a Delaware corporation and direct, wholly owned subsidiary of Parent (“Merger
Sub Corp”), Mustang Merger Sub II LLC, a Delaware limited liability company and a direct wholly owned subsidiary
of Parent (“Merger Sub LLC” and together with Merger Sub Corp, “Merger Sub”),
and Shareholder Representative Services LLC, solely in its capacity as the representative of the stockholders of the Company, have
entered into that certain Agreement and Plan of Merger and Reorganization (as amended from time to time, the “Merger
Agreement”), dated as of January 18, 2017, pursuant to which Merger Sub Corp will merge with and into the
Company (“Merger 1”), and immediately thereafter, the Company will merge with and into Merger Sub LLC,
with Merger Sub LLC as the surviving entity in such merger (“Merger 2” and together with Merger 1, the
“Mergers”), and Merger Sub LLC will continue as a direct wholly owned subsidiary of Parent; and

 

B.           As
of the date hereof, each Stockholder is the Beneficial Owner (as defined below) of, and has the sole right to vote and dispose
of, that number of each class of the issued and outstanding capital stock of Parent (the “Parent Shares”)
set forth opposite such Stockholder’s name on Schedule A hereto; and

 

C.           Concurrently
with the entry by the Company, Parent and Merger Sub into the Merger Agreement, and as a condition and inducement to the willingness
of the Company to enter into the Merger Agreement and incur the obligations set forth therein, the Company has required that the
Stockholders enter into this Agreement.

 

Accordingly, and in consideration
of the foregoing and the mutual representations, warranties, covenants and agreements contained herein, the parties hereto, intending
to be legally bound, hereby agree as follows:

 

ARTICLE I.

DEFINITIONS

 

Capitalized terms used
but not defined in this Agreement are used in this Agreement with the meanings given to such terms in the Merger Agreement. In
addition, for purposes of this Agreement:

 

“Affiliate”
means, with respect to any specified Person, a Person who, at the time of determination, directly or indirectly through one or
more intermediaries, controls, or is controlled by, or is under common control with, such specified Person. For purposes of this
Agreement, with respect to a Stockholder, “Affiliate” does not include Parent and the Persons that directly,
or indirectly through one or more intermediaries, are controlled by Parent. For the avoidance of doubt, no officer or director
of Parent will be deemed an Affiliate of another officer or director of Parent by virtue of his or her status as an officer or
director of Parent.

 

     

     

    

 

“Beneficially
Owned” or “Beneficial Ownership” with respect to any securities means having beneficial
ownership of such securities (as determined pursuant to Rule 13d-3 under the Exchange Act, disregarding the phrase “within
60 days” in paragraph (d)(1)(i) thereof), including pursuant to any agreement, arrangement or understanding, whether
or not in writing. Without duplicative counting of the same securities, securities Beneficially Owned by a Person include securities
Beneficially Owned by (i) all Affiliates of such Person, and (ii) all other Persons with whom such Person would constitute
a “group” within the meaning of Section 13(d) of the Exchange Act and the rules promulgated thereunder.

 

“Beneficial
Owner” with respect to any securities means a Person that has Beneficial Ownership of such securities.

 

“Subject Shares”
means, with respect to a Stockholder, without duplication, (i) the Parent Shares Beneficially Owned by such Stockholder on
the date hereof as described on Schedule A, (ii) any additional Parent Shares Beneficially Owned or acquired by such
Stockholder, including those over which such Stockholder acquires Beneficial Ownership from and after the date hereof, whether
pursuant to existing stock option agreements, warrants or otherwise, and (iii) any securities converted, exchanged or reclassified
into Parent Shares. Without limiting the other provisions of this Agreement, in the event that Parent changes the number of Parent
Shares issued and outstanding prior to the Termination Date as a result of a reclassification, stock split (including a reverse
stock split), stock dividend or distribution, combination, recapitalization, subdivision, or other similar transaction, the number
of Subject Shares subject to this Agreement will be equitably adjusted to reflect such change.

 

“Transfer”
means, with respect to a security, the sale, transfer, pledge, hypothecation, encumbrance, assignment or disposition of such security
or the Beneficial Ownership thereof, whether by operation of Law or otherwise, and each option, agreement, arrangement or understanding,
whether or not in writing, to effect any of the foregoing. As a verb, “Transfer” has a correlative meaning.

 

ARTICLE II.

COVENANTS OF STOCKHOLDERS

 

2.1           Irrevocable
Proxy. Concurrently with the execution of this Agreement, each Stockholder agrees to deliver to the Company a proxy in the
form attached hereto as Exhibit A (the “Proxy”), which will be irrevocable to the fullest extent
provided in Section 212 of the Delaware General Corporation Law (the “DGCL”), with respect to the
Subject Shares referred to therein.

 

2.2           Agreement
to Vote.

 

(a)          At
each and every meeting of the stockholders of Parent held prior to the Termination Date, however called, and at every adjournment
or postponement thereof prior to the Termination Date, or in connection with each and every written consent of, or any other action
by, the stockholders of Parent given or solicited prior to the Termination Date, each Stockholder will vote or provide a consent
with respect to, or shall cause the holder of record on any applicable record date to vote or provide a consent with respect to,
all of the Subject Shares entitled to vote or to consent thereon (i) in favor of the adoption of the Merger Agreement, the
issuance of Parent Shares to the Company Stockholders pursuant to the terms of the Merger Agreement, and any other actions contemplated
by the Merger Agreement, including the Parent Stockholder Proposals, and (ii) against any amendment of Parent’s certificate
of incorporation or bylaws or any other proposal or transaction involving Parent, the effect of which amendment or other proposal
or transaction is to delay, impair, prevent or nullify the Mergers or the transactions contemplated by the Merger Agreement or
change in any manner the voting rights of any capital stock of Parent, and against any other action or agreement that would result
in a breach in any material respect of any covenant, representation or warranty or any other obligation or agreement of Parent
or its stockholders under the Merger Agreement.

 

    	 	2	 

     

    

 

(b)          No
Stockholder will enter into any agreement with any Person (other than the Company) prior to the Termination Date (with respect
to periods prior to or after the Termination Date) directly or indirectly to vote, consent, grant any proxy or give instructions
with respect to the voting of, the Subject Shares in respect of the matters described in Section 2.2(a) hereof, or
the effect of which would be inconsistent with or violate any provision contained in this Section 2.2. Any vote or consent
(or withholding of consent) by any Stockholder that is not in accordance with this Section 2.2 will be considered null and
void, and the provisions of the Proxy will be deemed to take immediate effect.

 

2.3           Revocation
of Proxies; Cooperation. Each Stockholder agrees as follows:

 

(a)          Such
Stockholder hereby represents and warrants that any proxies heretofore given in respect of the Subject Shares with respect to the
matters described in Section 2.2(a) hereof are not irrevocable, and such Stockholder hereby revokes any and all prior
proxies with respect to such Subject Shares as they relate to such matters. Prior to the Termination Date, such Stockholder will
not directly or indirectly grant any proxies or powers of attorney with respect to the matters set forth in Section 2.2(a)
hereof (other than to the Company), deposit any of the Subject Shares or enter into a voting agreement (other than this Agreement)
with respect to any of the Subject Shares relating to any matter described in Section 2.2(a).

 

(b)          Such
Stockholder will provide any information reasonably requested by the Company or Parent for any regulatory application or filing
sought for such transactions.

 

2.4           No
Transfer of Subject Shares; Publicity. Each Stockholder agrees that:

 

(a)          It
(i) will not Transfer or agree to Transfer any of the Subject Shares or, with respect to any matter described in Section 2.2(a),
grant any proxy or power-of-attorney with respect to any of the Subject Shares, (ii) will take all action reasonably necessary
to prevent creditors in respect of any pledge of the Subject Shares from exercising their rights under such pledge, and (iii) will
not take any action that would make in a material respect any of its representations or warranties contained herein untrue or incorrect
or would have the effect of preventing or disabling such Stockholder from performing any of its material obligations hereunder;
provided, however, that Stockholder may transfer the Subject Shares (1) to Affiliates (including, for the avoidance of doubt,
if Stockholder is a corporation, partnership, limited liability company, investment fund, trust or other business entity, such
investment funds or other business entities controlled or managed by, or that controls or manages, or under common management with,
the Stockholder) or charitable organizations, (2) if Stockholder is an individual, to any member of Stockholder’s immediate
family, or to a trust for the benefit of Stockholder or any member of Stockholder’s immediate family for estate planning
purposes or for the purposes of personal tax planning, or upon the death of Stockholder, by will or intestacy, (3) if Stockholder
is a corporation, partnership, limited liability company, investment fund or other business entity, as part of a disposition, transfer
or distribution by the Stockholder to its equity holders, (4) if the Stockholder is a trust, to a trustor or beneficiary of the
trust; or (5) to a nominee or custodian of a Person or entity to whom a disposition or transfer would be permissible under this
clause (any such transferee permitted under clauses (1) through (5), a “Permitted Transferee”); provided,
further, that any such Transfer shall be permitted only if, as a precondition to such Transfer, the Permitted Transferee agrees
in writing to be bound by all of the terms of this Agreement.

 

    	 	3	 

     

    

 

(b)          Unless
required by applicable Law or permitted by the Merger Agreement, such Stockholder will not, and will not authorize or direct any
of its Affiliates, Representatives, employees or agents to, make any press release or public announcement with respect to this
Agreement or the Merger Agreement or the transactions contemplated hereby or thereby, without the prior written consent of the
Company in each instance.

 

2.5           Resignation.
Each Stockholder that is a director or officer of Parent and who is not selected by Parent to serve as a director of Parent immediately
after the Effective Time pursuant to the Merger Agreement, hereby resigns as a director and officer of Parent and every direct
or indirect subsidiary or other Affiliate thereof, effective as of immediately prior to the Effective Time.

 

2.6           Non-Solicitation.
Each Stockholder hereby agrees to comply with the obligations of Parent, its Subsidiaries and Representatives of Parent or any
of its Subsidiaries set forth in Section 4.5(b) of the Merger Agreement, and agree not to take any action that would violate or
breach, or cause the violation or breach of, Section 4.5(b) of the Merger Agreement.

 

ARTICLE III.

REPRESENTATIONS, WARRANTIES AND ADDITIONAL COVENANTS OF STOCKHOLDERS

 

Each Stockholder represents,
warrants and covenants to the Company that:

 

3.1           Ownership.
Such Stockholder is the sole Beneficial Owner or the record owner of the Subject Shares identified opposite such Stockholder’s
name on Schedule A and such Subject Shares constitute all of the capital stock of Parent Beneficially Owned by such Stockholder.
Such Stockholder has good and valid title to all of the Subject Shares, free and clear of all Liens, claims, options, proxies,
voting agreements and security interests and has the sole right to such Subject Shares and there are no restrictions on rights
of disposition or other Liens pertaining to such Subject Shares. None of the Subject Shares is subject to any voting trust or other
contract with respect to the voting thereof, and no proxy, power of attorney or other authorization has been granted with respect
to any of such Subject Shares.

 

    	 	4	 

     

    

 

3.2           Authority
and Non-Contravention.

 

(a)          Such
Stockholder has all necessary power and authority to execute and deliver this Agreement, to perform its obligations hereunder and
to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by such Stockholder and the consummation
by such Stockholder of the transactions contemplated hereby have been duly and validly authorized by all necessary action, and
no other proceedings on the part of such Stockholder are necessary to authorize this Agreement or to consummate the transactions
contemplated hereby.

 

(b)          This
Agreement has been duly and validly executed and delivered by such Stockholder and, assuming due authorization, execution and delivery
of this Agreement by the Company, constitutes the legal, valid and binding obligation of such Stockholder, enforceable against
such Stockholder in accordance with its terms except (i) to the extent limited by applicable bankruptcy, insolvency or similar
laws affecting creditors’ rights and (ii) the remedy of specific performance and injunctive and other forms of equitable
relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

 

(c)          Such
Stockholder is not nor will it be required to make any filing with or give any notice to, or to obtain any consent from, any Person
in connection with the execution, delivery or performance of this Agreement or obtain any permit or approval from any Governmental
Entity for any of the transactions contemplated hereby, except to the extent required by Section 13 or Section 16 of
the Exchange Act and the rules promulgated thereunder.

 

(d)          Neither
the execution and delivery of this Agreement by such Stockholder nor the consummation of the transactions contemplated hereby will
directly or indirectly (whether with notice or lapse of time or both) (i) conflict with, result in any violation of or constitute
a default by such Stockholder under any mortgage, bond, indenture, agreement, instrument or obligation to which such Stockholder
is a party or by which it or any of the Subject Shares are bound, or violate any permit of any Governmental Entity, or any applicable
Law to which such Stockholder, or any of the Subject Shares, may be subject, or violate any organizational documents of such Stockholder
or (ii) result in the imposition or creation of any Lien upon or with respect to any of the Subject Shares; except, in each
case, for conflicts, violations, defaults or Liens that would not individually or in the aggregate be reasonably expected to prevent
or materially impair or delay the performance by such Stockholder of its obligations hereunder.

 

(e)          Such
Stockholder has sole voting power and sole power to issue instructions with respect to the matters set forth in Article II hereof
and sole power to agree to all of the matters set forth in this Agreement, in each case with respect to all of the Subject Shares,
with no limitations, qualifications or restrictions on such rights.

 

3.3           Total
Shares. Except as set forth on Schedule A, no Stockholder is the Beneficial Owner of, and does not have (whether currently,
upon lapse of time, following the satisfaction of any conditions, upon the occurrence of any event or any combination of the foregoing)
any right to acquire, any Parent Shares or any securities convertible into or exchangeable or exercisable for Parent Shares. No
Stockholder has any other interest in or voting rights with respect to any Parent Shares or any securities convertible into or
exchangeable or exercisable for Parent Shares.

 

    	 	5	 

     

    

 

3.4           Reliance.
Each Stockholder understands and acknowledges that the Company is entering into the Merger Agreement in reliance upon Stockholders’
execution, delivery and performance of this Agreement.

 

ARTICLE IV.

REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY

 

The Company represents,
warrants and covenants to Stockholders that:

 

(a)          The
Company has all necessary corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder.
The execution and delivery by the Company of this Agreement and the consummation by the Company of the transactions contemplated
hereby have been duly and validly authorized by the Company and no other corporate proceedings on the part of the Company are necessary
to authorize this Agreement or to consummate the transactions contemplated hereby.

 

(b)          This
Agreement has been duly and validly executed and delivered by the Company and, assuming due authorization, execution and delivery
of this Agreement by the Stockholders, constitutes the legal, valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms, except (i) to the extent limited by applicable bankruptcy, insolvency or similar
laws affecting creditors’ rights and (ii) the remedy of specific performance and injunctive and other forms of equitable
relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

 

ARTICLE V.

DISSENTERS’ RIGHTS.

 

5.1           Stockholder
hereby waives and agrees not to exercise any rights of appraisal or any dissenters’ rights that Stockholder may have (whether
under applicable Law or otherwise) or could potentially have or acquire in connection with the Merger.

 

ARTICLE VI.

TERM AND TERMINATION

 

6.1           This
Agreement will become effective upon its execution by the Stockholders and the Company. This Agreement will terminate upon the
earliest of (a) the Effective Time, (b) the termination of the Merger Agreement in accordance with Article 7 thereof, or (c) written
notice by the Company to the Stockholders of the termination of this Agreement (the date of the earliest of the events described
in clauses (a), (b) and (c), the “Termination Date”). Notwithstanding the foregoing, Article VII of this
Agreement shall survive any termination hereof.

 

    	 	6	 

     

    

 

ARTICLE VII.

GENERAL PROVISIONS

 

7.1           Action
in Stockholder Capacity Only. Each Stockholder is entering into this Agreement solely in such Stockholder’s capacity
as a record holder or Beneficial Owner, as applicable, of the Subject Shares and not in such Stockholder’s capacity as a
director or officer of Parent. Notwithstanding any asserted conflict, nothing herein will limit or affect any Stockholder’s
ability to act as an officer or director of Parent, including, if Stockholder is a director of Parent, its ability to vote in favor
of a Parent Change of Recommendation, or to make any presentations to the Parent Board of Directors or take any other action that
he or she determines to be necessary or appropriate in his or her discretion, without regard to this Agreement or any conflict
of interest.

 

7.2           No
Ownership Interest. Nothing contained in this Agreement will be deemed to vest in the Company or any of its Affiliates any
direct or indirect ownership or incidents of ownership of or with respect to the Subject Shares. All rights, ownership and economic
benefits of and relating to the Subject Shares will remain and belong to the Stockholders, and neither the Company nor any of its
Affiliates will have any authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies
or operations of Parent or exercise any power or authority to direct any Stockholder in the voting of any of the Subject Shares,
except as otherwise expressly provided herein or in the Merger Agreement.

 

7.3           Notices.
All notices and other communications hereunder shall be in writing (including email or similar
writing) and must be given:

 

If to the Company, to:

 

Altimmune, Inc.

19 Firstfield Road, Suite 200

Gaithersburg, MD 20878 

		Attention:	Bill Enright

		Email:	enright@altimmune.com

  

with a copy (which will not constitute
notice) to:

 

Proskauer Rose LLP

1 International Place

Boston, MA 02110

		Attention:	Ori Solomon

		Email:	osolomon@proskauer.com

  

If to any Stockholder, to such Stockholder
at its address set forth on Schedule A,

 

with a copy (which will not constitute
notice) to:

 

Dentons US LLP

1221 Avenue of the Americas

New York, NY 10020

		Attention:	Jeffrey Baumel

Ilan Katz

		Email:	jeffrey.baumel@dentons.com

ilan.katz@dentons.com

 

 

or such other physical address or email address
as a party may hereafter specify for the purpose by notice to the other parties hereto. Each notice, consent, waiver or other communication
under this Agreement will be effective only (i) if given by email, when the email is transmitted to the email address specified
in this Section 7.3 or (ii) if given by overnight courier or personal delivery when delivered at the physical address specified
in this Section 7.3.

 

    	 	7	 

     

    

 

7.4           Further
Actions. Upon the request of any party to this Agreement, the other party will (a) furnish to the requesting party any
additional information, (b) execute and deliver, at their own expense, any other documents and (c) take any other actions
as the requesting party may reasonably require to more effectively carry out the intent of this Agreement. Each Stockholder hereby
agrees that Parent may publish and disclose in the Form S-4 Registration Statement and Proxy Statement (including all documents
and schedules filed with the SEC) such Stockholder’s identity and ownership of Subject Shares and the nature of such Stockholder’s
commitments, arrangements, and understandings under this Agreement and may further file this Agreement as an exhibit to the Form
S-4 Registration Statement or in any other filing made by the Parent with the SEC relating to the Merger Agreement or the transactions
contemplated thereby.

 

7.5           Entire
Agreement and Modification. This Agreement, the Proxy and any other documents delivered by the parties in connection herewith
constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements
and understandings, both written and oral, between the parties with respect to its subject matter and constitute (along with the
documents delivered pursuant to this Agreement) a complete and exclusive statement of the terms of the agreement between the parties
with respect to its subject matter. This Agreement may not be amended, supplemented or otherwise modified except by a written document
executed by the party against whose interest the modification will operate. The parties will not enter into any other agreement
inconsistent with the terms and conditions of this Agreement and the Proxy, or that addresses any of the subject matters addressed
in this Agreement and the Proxy.

 

7.6           Drafting
and Representation. The parties agree that the terms and language of this Agreement were the result of negotiations between
the parties and, as a result, there will be no presumption that any ambiguities in this Agreement will be resolved against any
party. Any controversy over construction of this Agreement will be decided without regard to events of authorship or negotiation.

 

7.7           Severability.
Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction will, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without affecting the validity or enforceability of the remaining provisions
hereof. Any such prohibition or unenforceability in any jurisdiction will not invalidate or render unenforceable such provision
in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, the provision will be interpreted
to be only so broad as is enforceable.

 

7.8           No
Third-Party Rights. No Stockholder may assign any of its rights or delegate any of its obligations under this Agreement without
the prior written consent of the Company. The Company may not assign any of its rights or delegate any of its obligations under
this Agreement with respect to any Stockholder without the prior written consent of such Stockholder. This Agreement will apply
to, be binding in all respects upon, and inure to the benefit of each of the respective successors, personal or legal representatives,
heirs, distributes, devisees, legatees, executors, administrators and permitted assigns of any Stockholder and the successors and
permitted assigns of the Company. Nothing expressed or referred to in this Agreement will be construed to give any Person, other
than the parties to this Agreement, any legal or equitable right, remedy or claim under or with respect to this Agreement or any
provision of this Agreement except such rights as may inure to a successor or permitted assignee under this Section.

 

    	 	8	 

     

    

  

7.9           Enforcement
of Agreement. Each Stockholder acknowledges and agrees that the Company could be damaged irreparably if any of the provisions
of this Agreement are not performed in accordance with their specific terms and that any breach of this Agreement by any Stockholder
could not be adequately compensated by monetary damages. Accordingly, each Stockholder agrees that, (a) it will waive, in
any action for specific performance, the defense of adequacy of a remedy at law, and (b) in addition to any other right or
remedy to which the Company may be entitled, at law or in equity, the Company will be entitled to enforce any provision of this
Agreement by a decree of specific performance and to temporary, preliminary and permanent injunctive relief to prevent breaches
or threatened breaches of any of the provisions of this Agreement, without posting any bond or other undertaking.

 

7.10         Waiver.
The rights and remedies of the parties to this Agreement are cumulative and not alternative. Neither any failure nor any delay
by a party in exercising any right, power or privilege under this Agreement, the Proxy or any of the documents referred to in this
Agreement will operate as a waiver of such right, power or privilege, and no single or partial exercise of any such right, power
or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right,
power or privilege. To the maximum extent permitted by applicable Law, (a) no claim or right arising out of this Agreement,
the Proxy or any of the documents referred to in this Agreement can be discharged by one party, in whole or in part, by a waiver
or renunciation of the claim or right unless in a written document signed by the other party, (b) no waiver that may be given
by a party will be applicable except in the specific instance for which it is given, and (c) no notice to or demand on one
party will be deemed to be a waiver of any obligation of that party or of the right of the party giving such notice or demand to
take further action without notice or demand as provided in this Agreement, the Proxy or the documents referred to in this Agreement.

 

7.11         Governing
Law. This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto will
be governed by, construed under and enforced in accordance with the laws of the State of Delaware, without giving effect to principles
of conflict or choice of laws which would result in the application of the laws of any other jurisdiction.

 

7.12         Consent
to Jurisdiction. Any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of
or in connection with, this Agreement, the Proxy or the transactions contemplated hereby or thereby will be brought exclusively
in the United States District Court for the District of Delaware or in the Court of Chancery of the State of Delaware and each
of the parties hereto hereby consents to the exclusive jurisdiction of those courts (and of the appropriate appellate courts therefrom)
in any suit, action or proceeding and irrevocably waives, to the fullest extent permitted by applicable Law, any objection which
it may now or hereafter have to the laying of the venue of any suit, action or proceeding in any of those courts or that any suit,
action or proceeding which is brought in any of those courts has been brought in an inconvenient forum. Process in any suit, action
or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any of the named
courts. Without limiting the foregoing, each party agrees that service of process on it by notice as provided in Section 7.3
will be deemed effective service of process. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED
BY LAW, ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY.

 

    	 	9	 

     

    

 

7.13         Counterparts.
This Agreement may be executed in any number of counterparts, each of which will be deemed to be an original, but all of which,
taken together, will constitute one and the same instrument. An electronic copy of a party’s signature (including signatures
in Adobe PDF or similar format) shall be deemed an original signature for purposes hereof.

 

7.14         Expenses.
Except as otherwise provided in this Agreement, all costs and expenses incurred in connection with this Agreement and the transactions
contemplated hereby will be paid by the party incurring such expenses.

 

7.15         Headings;
Construction. The headings contained in this Agreement are for reference purposes only and will not affect in any way the meaning
or interpretation of this Agreement. In this Agreement (a) words denoting the singular include the plural and vice versa,
(b) ”it” or “its” or words denoting any gender include all genders and (c) the word “including”
means “including without limitation,” whether or not expressed.

 

[Signature page follows]

 

    	 	10	 

     

    

 

IN WITNESS WHEREOF, the
parties hereto have caused this Parent Voting Agreement to be duly executed as of the day and year first above written.

 

	THE COMPANY:	ALTIMMUNE, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

STOCKHOLDERS:

 

	 	 
	 	John M. Gill
	 	 
	 	 
	 	Philip MacNeill
	 	 
	 	 
	 	John Troyer, Ph.D.
	 	 
	 	 
	 	Eric I. Richman
	 	 
	 	 
	 	Jeffrey W. Runge, M.D.
	 	 
	 	 
	 	Mitchel B. Sayare, Ph.D.
	 	 
	 	 
	 	Derace L. Schaffer, M.D.
	 	 
	 	 
	 	Steven St. Peter, M.D.
	 	 
	 	 
	 	Jeffrey Steinberg

 

     

     

    

 

SCHEDULE
A

 

STOCKHOLDERS

 

	NAME AND

ADDRESS OF STOCKHOLDERS	 	Parent SHARES

BENEFICIALLY OWNED
	 	 	 
	John M. Gill

c/o PharmAthene, Inc.,

One Park Place, Suite 450

Annapolis, MD 21401	 	902,244
	 	 	 
	Philip MacNeill

c/o PharmAthene, Inc.,

One Park Place, Suite 450

Annapolis, MD 21401	 	118,689
	 	 	 
	John Troyer, Ph.D.

c/o PharmAthene, Inc.,

One Park Place, Suite 450

Annapolis, MD 21401	 	170,775
	 	 	 
	Eric I. Richman

c/o PharmAthene, Inc.,

One Park Place, Suite 450

Annapolis, MD 21401	 	1,643,055
	 	 	 
	Jeffrey W. Runge, M.D.

c/o PharmAthene, Inc.,

One Park Place, Suite 450

Annapolis, MD 21401	 	197,700
	 	 	 
	Mitchel B. Sayare, Ph.D.

c/o PharmAthene, Inc.,

One Park Place, Suite 450

Annapolis, MD 21401	 	295,500
	 	 	 
	Derace L. Schaffer, M.D.

c/o PharmAthene, Inc.,

One Park Place, Suite 450

Annapolis, MD 21401	 	1,207,711
	 	 	 
	Steven St. Peter, M.D.
 c/o PharmAthene, Inc.,

One Park Place, Suite 450

                                 Annapolis, MD 21401
	 	205,004
	 	 	 
	Jeffrey Steinberg

                                 c/o PharmAthene, Inc.,

One Park Place, Suite 450

                                 Annapolis, MD 21401
	 	121,065

 

     

     

    

 

EXHIBIT
A

 

IRREVOCABLE
PROXY

 

From and after the date
hereof and until the Termination Date (as defined below), on which date this irrevocable proxy (the “proxy”)
will terminate and be of no further force or effect, the undersigned stockholder (“Stockholder”) of PharmAthene,
Inc., a Delaware corporation (“Parent”), hereby irrevocably (to the fullest extent permitted by Section 212
of the Delaware General Corporation Law) grants to, and appoints, Altimmune, Inc., a Delaware corporation (the “Company”),
and any designee of the Company, and each of them individually, as the sole and exclusive attorney and proxy of the undersigned,
with full power of substitution and re-substitution, to vote the Subject Shares (as defined in the Voting Agreement) or to issue
instructions to the record holder to vote the Subject Shares, or grant a consent or approval in respect of the Subject Shares or
issue instructions to the record holder to grant a consent or approval in respect of the Subject Shares, in a manner consistent
with Section 2.2 of the Voting Agreement (as defined below). Upon the undersigned’s execution of this Proxy, any and all
prior proxies given by the undersigned with respect to any Subject Shares relating to the voting rights expressly provided herein
are hereby revoked and the undersigned agrees not to grant any subsequent proxies with respect to the Subject Shares relating to
such voting rights at any time prior to the Termination Date, on which date this proxy will terminate and be of no further force
or effect.

 

This Proxy is irrevocable,
is coupled with an interest and is granted pursuant to that certain Parent Voting Agreement (as amended from time to time, the
“Voting Agreement”) of even date herewith, by and among the Company and Stockholder, and is granted in
consideration of the Company entering into the Merger Agreement (as defined in the Voting Agreement). As used herein, the term
“Termination Date,” and all capitalized terms used herein and not otherwise defined, will have the meanings
set forth in the Voting Agreement. The Stockholder agrees that this proxy will be irrevocable until the Termination Date,
on which date this proxy will terminate and be of no further force or effect, and is coupled with an interest sufficient at
law to support an irrevocable proxy and given to the Company as an inducement to enter into the Merger Agreement and, to the extent
permitted under applicable law, will be valid and binding on any Person to whom Stockholder may transfer any of his, her or its
Subject Shares whether as permitted by or in breach of the Voting Agreement. The Stockholder hereby ratifies and confirms all
that such irrevocable proxy may lawfully do or cause to be done by virtue hereof.

 

The attorneys and proxies
named above, and each of them, are hereby authorized and empowered by the undersigned, at any time prior to the Termination Date,
on which date this proxy will terminate and be of no further force or effect, to act as the undersigned’s attorney and proxy
to vote the Subject Shares, and to exercise all voting and other rights of the undersigned with respect to the Subject Shares (including,
without limitation, the power to execute and deliver written consents pursuant to Section 228 of the Delaware General Corporation
Law), at every annual, special or adjourned meeting of the stockholders of Parent and in every written consent in lieu of such
meeting in a manner consistent with Section 2.2 of the Voting Agreement.

 

     

     

    

 

This Proxy will be binding
upon the heirs, estate, executors, personal representatives, successors and assigns of Stockholder (including any transferee of
any of the Subject Shares), and all authority herein conferred or agreed to be conferred will survive the death or incapacity of
the Stockholder.

 

If any provision of this
Proxy or any part of any such provision is held under any circumstances to be invalid or unenforceable in any jurisdiction, then
(a) such provision or part thereof will, with respect to such circumstances and in such jurisdiction, be deemed amended to
conform to applicable laws so as to be valid and enforceable to the fullest possible extent, (b) the invalidity or unenforceability
of such provision or part thereof under such circumstances and in such jurisdiction will not affect the validity or enforceability
of such provision or part thereof under any other circumstances or in any other jurisdiction, and (c) the invalidity or unenforceability
of such provision or part thereof will not affect the validity or enforceability of the remainder of such provision or the validity
or enforceability of any other provision of this Proxy. Each provision of this Proxy is separable from every other provision of
this Proxy, and each part of each provision of this Proxy is separable from every other part of such provision.

 

With respect to any Subject
Shares that are Beneficially Owned (as defined in the Voting Agreement) by the Stockholder but are not held of record by the Stockholder,
the Stockholder shall take all action necessary to cause the record holder of such Subject Shares to grant the irrevocable proxy
and take all other actions provided for in this proxy with respect to such Subject Shares.

 

Dated: January 18, 2017

 

	 	 	 
	 	[NAME OF INDIVIDUAL]	 
	 	 	 
	 	[NAME OF ENTITY]	 
	 	 	 	 
	 	By: 	 	 
	 	 	Name:	 
	 	 	Title:	 

 

    	 	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]